Pulmonary Lymphoepithelioma-like Carcinoma

Sathirareuangchai, Sakda; Hirata, Kirk

doi:10.5858/arpa.2018-0149-rs

Cited by 33 publications

(40 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other primary LELC previously described in foregut‐derived organs, including the salivary gland, thymus, and stomach demonstrated close association with EBV infection, but interestingly this association was not found in the gynecologic tract LELCs, such as those in the cervix and vagina 14 . For pulmonary LELC, Ccell‐free EBV DNA can be found in the plasma directly, 15 and positive EBV‐encoded RNA staining in nuclei of tumor cells could also be regarded as reliable evidence for latent EBV detection 16 …”

Section: Discussionmentioning

confidence: 77%

“…The mutational status of epidermal growth factor receptor (EGFR) (exons [18][19][20][21], KRAS (exons 2-3), and BRAF (exons [11][12][13][14][15] were determined using direct dideoxynucleotide sequencing and verified by DNA-sequencing analysis. With the use of complementary DNA, primers were designed to amplify all known fusion variants to detect ALK and ROS1 fusions.…”

Section: Immunohistochemical Staining and Genetic Mutation Detectionmentioning

confidence: 99%

See 1 more Smart Citation

Clinicopathological and prognostic analyses of 86 resected pulmonary lymphoepithelioma‐like carcinomas

Chen

et al. 2020

Journal of Surgical Oncology

View full text Add to dashboard Cite

BackgroundPulmonary lymphoepithelioma‐like carcinoma (LELC) is a rare subtype of primary lung cancer. The present study aims at investigating clinicopathological features and prognostic characteristics of the resected pulmonary LELC.MethodsPatients with resected pulmonary LELC were identified in our hospital from December 2008 to December 2018. Data of these patients were retrospectively reviewed, clinicopathological features and prognostic characteristics were analyzed subsequently.ResultsIn total, 86 patients were enrolled in the study, including 39 (45.3%) males and 47 (54.7%) females. Most of the serum tumor markers were normal. Immunohistochemical staining result showed frequent differentiation traits of epithelial tissue such. Positive PD‐L1 (15 of 19, 78.9%) and PD‐1 (13 of 17, 76.5%) were also common, but cancer‐related genetic mutation was scarce (1 of 47, 2.1%). Survival analyses demonstrated that the N stage (p = .011) and extent of resection (p = .023) were identified as independent predictive factors for overall survival.ConclusionsPulmonary LELC is a distinctive subtype of lung cancer with several exclusive traits, such as the trend to happen among nonsmoking young people, epithelial origin of tumor differentiation, frequent expression of the immune checkpoint, and scarce presence of driver mutation. In addition, pulmonary LELC was apt to get a favorable outcome, especially in cases diagnosed and treated in the early stage.

show abstract

Section: Discussionmentioning

confidence: 77%

Section: Immunohistochemical Staining and Genetic Mutation Detectionmentioning

confidence: 99%

Clinicopathological and prognostic analyses of 86 resected pulmonary lymphoepithelioma‐like carcinomas

Chen

et al. 2020

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…In previous studies, PPLELC primarily occurred in young individuals and non-smokers without sexual predilection [ 10 , 32 , 38 , 39 ]. The proportions reported by Qin et al [ 38 ] were 71.8% and 72.9%, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…Except for that, several distinct morphologic characteristics were observed in PPLELC including spread through alveolar spaces, lepidic spreading pattern, focal keratinization and granulomatous inflammation [37]. In previous studies, PPLELC primarily occurred in young individuals and non-smokers without sexual predilection [10,32,38,39]. The proportions reported by Qin et al [38] were 71.8% and 72.9%, respectively.…”

Section: Plos Onementioning

confidence: 93%

The clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma: A systematic review and meta-analysis

Tang

Chen

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

Background Primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) was a sparse subtype of unclassified lung cancer. The clinicopathologic features, prognostic factors and multimodality treatment regimens of LELC remain inconclusive. We conducted this systematic review and meta-analysis to address this deficit in current knowledge. Methods We searched PubMed, Embase, and Web of Science to filtrate studies investigating on clinical features and prognostic factors of LELC up to Sep 9 th , 2020. Fixed and random effect models were generated to present the incorporated hazard ratios (HR) and odds ratios (OR) with 95% confidence intervals (CI). The quality and heterogeneity of the included studies were also evaluated carefully. Results This systematic review and meta-analysis included 13 retrospective studies with a total of 1294 patients. The incidence of programmed cell death-ligand 1 (PD-L1) expression in PPLELC varied from 63.3% to 75.8%. Positive PD-L1 expression was more likely to be found in patients under 60 years old (OR = 2.16, 95%CI: 1.19-3.89, P = 0.01) and was associated with worse disease-free survival (DFS) compared with negative PD-L1 expression (HR = 2.99, 95%CI: 1.23-7.28, P = 0.02). The pooled results showed that stage was the prognostic factor for both overall survival (OS) and DFS. Moreover, a significantly better outcome of PPLELC was observed in men (HR = 0.56, 95%CI: 0.33-0.95, P = 0.03) and patients who received radiation (HR = 0.46, 95%CI: 0.22-0.96, P = 0.04).

show abstract

“…Morphological features are similar to those of undifferentiated nasopharyngeal carcinoma. 5 , 6 Typically, poorly differentiated tumor cells and a large number of lymphocyte infiltration can be observed. 7 , 8 LELC may be related to EB virus infection, and has a higher incidence in Southeast Asia, such as Guangdong, Hongkong, Taiwan, and Singapore, than in Europe and the US.…”

Section: Introductionmentioning

confidence: 99%

Pulmonary Lymphoepithelioma-Like Carcinoma Treated with Immunotherapy or Chemotherapy: A Single Institute Experience

Zheng

Wang

et al. 2021

OTT

View full text Add to dashboard Cite

Background Lymphoepithelioma-like carcinoma (LELC) is a rare malignant tumor of the lung. It is related to EB virus infection. Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) are rarely found in this disease, while high level programmed cell death ligand 1 (PD-L1) expression is observed. Here a series of patients with advanced LELC treated with immunotherapy were summarized. Methods This retrospective, observational study was conducted in patients who were pathologically confirmed, metastatic or recurrent LELC patients. Patients were prescribed with either chemotherapy or immunotherapy, according to treating physicians’ discretion. Results A total of 27 patients were included in our study, 10 with immunotherapy (ICI group) and 17 with chemotherapy (Chemo group). The objective response rates (ORR) of the two groups were 80.0% and 70.5% (p=0.678), and disease control rates (DCR) were 100% and 88.2% (p=0.516). However, the response depth was better in the ICI group. Although the cohort of patients in the ICI group was in a disadvantageous state (both up-front and salvage), the progression-free survival (PFS) was much longer (15.0 and 7.9 m, p=0.005). The 1-year PFS rate in the ICI group was also much higher (40% and 5.9%, p=0.047). Conclusion This study implicated the high efficiency of ICI therapy in this disease.

show abstract

Pulmonary Lymphoepithelioma-like Carcinoma

Cited by 33 publications

References 28 publications

Clinicopathological and prognostic analyses of 86 resected pulmonary lymphoepithelioma‐like carcinomas

Clinicopathological and prognostic analyses of 86 resected pulmonary lymphoepithelioma‐like carcinomas

The clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma: A systematic review and meta-analysis

Pulmonary Lymphoepithelioma-Like Carcinoma Treated with Immunotherapy or Chemotherapy: A Single Institute Experience

Contact Info

Product

Resources

About